SAN FRANCISCO, CA--(Marketwired - October 03, 2016) - Australian regenerative medicine company Regeneus Ltd. (
Included in this article is: Regeneus Ltd.
According to Edison Investment Research analyst Dennis Hulme, Regeneus "is in advanced discussions with a large Japanese company regarding licensing Progenza for the Japanese market, and anticipates converting these discussions into a binding arrangement by the end of the current quarter."
In his Sept. 14 research report, Hulme noted that "signing up a manufacturing and commercial partner for Progenza in Japan would provide significant validation of the commercial value of the company's technology and represents near-term potential upside."
In addition, "Upfront fees and milestone payments from the potential deal could offer a source of nondilutive funding for the company's ongoing work on new product development," Hulme stated. "In addition, we would expect a partner to either fully or partly cover the costs of the planned Phase 2 trial of Progenza in patients with osteoarthritis of the knee."
Continue reading this article: Stock-Moving Catalysts Anticipated for Regeneus in Q4/16
About Streetwise Reports - The Life Sciences Report
Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
The following companies mentioned in the article are sponsors of Streetwise Reports: Regeneus Ltd. The companies mentioned in this article were not involved in any aspect of the article preparation. Streetwise Reports does not accept stock in exchange for its services. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
Please see the end of the article for the complete disclosure: Stock-Moving Catalysts Anticipated for Regeneus in Q4/16
Carrie Beal Amaro